ZIVO Stock Price, Zivo Bioscience, Inc. Quote, Chart

Market Summary

USD7.980.00

Market Closed

0.00%

ZIVO Stock Price

View Fullscreen

ZIVO RSI Chart

ZIVO Valuation

Market Cap

22.6M

Price/Earnings (Trailing)

-3.19

Price/Sales (Trailing)

356.62

Price/Free Cashflow

-4.21

ZIVO Price/Sales (Trailing)

ZIVO Profitability

Return on Equity

312.16%

Return on Assets

-867.54%

Free Cashflow Yield

-23.76%

ZIVO Fundamentals

ZIVO Revenue

Revenue (TTM)

63.4K

Rev. Growth (Yr)

-86.56%

Rev. Growth (Qtr)

202.71%

ZIVO Earnings

Earnings (TTM)

-7.1M

Earnings Growth (Yr)

35.21%

Earnings Growth (Qtr)

33.01%

Breaking Down ZIVO Revenue

Last 7 days

-0.9%

Last 30 days

-2.1%

Last 90 days

-5.1%

Trailing 12 Months

152.6%

How does ZIVO drawdown profile look like?

ZIVO Financial Health

Current Ratio

0.23

Debt/Equity

-6.19

Debt/Cashflow

-0.38

ZIVO Investor Care

Shares Dilution (1Y)

80.39%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	63.4K	0	0	0
2023	0	0	0	27.6K
2021	0	0	0	0
2020	0	0	0	0
2019	1.8M	2.3M	2.4M	2.0M
2018	2.0M	2.1M	1.4M	2.0M
2017	2.0M	1.0M	1.9M	1.8M
2016	1.3M	1.5M	1.7M	1.9M
2015	0	0	0	1.1M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Zivo Bioscience, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Jan 02, 2024	cornell alison a	bought	49,999	1.2	41,666	-
Dec 29, 2023	maggiore christopher d.	bought	205,000	1.3	157,692	-
Dec 13, 2023	maggiore christopher d.	bought	45,000	1.00	45,000	-
Dec 19, 2022	masterson nola e	bought	792	2.64	300	-
Dec 19, 2022	payne john bernard	bought	142	2.5	57.00	president and ceo
Dec 13, 2022	cornell alison a	bought	36,000	3.00	12,000	-
Sep 14, 2022	maggiore christopher d.	bought	25,447	3.53438	7,200	-
Feb 11, 2022	maggiore christopher d.	bought	173,952	3.8686	44,965	-
Feb 10, 2022	maggiore christopher d.	bought	65,451	3.635	18,006	-

Which funds bought or sold ZIVO recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 09, 2024	BARTLETT & CO. WEALTH MANAGEMENT LLC	sold off	-100	-216	-	-%
Jan 08, 2024	Bartlett & Co. LLC	new	-	-	-	-%
Jan 08, 2024	Bartlett & Co. LLC	sold off	-100	-1,000	-	-%
Nov 13, 2023	Ayrton Capital LLC	unchanged	-	-7,420,000	21,885,000	0.15%
Nov 03, 2023	Column Capital Advisors, LLC	unchanged	-	-13,440	15,600	-%

Are Funds Buying or Selling ZIVO?

Are funds buying ZIVO calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ZIVO

No. of Funds

Unveiling Zivo Bioscience, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 09, 2024	strome mezzanine fund, lp	2.1%	57,506	SC 13D/A
Jan 22, 2024	maggiore christopher d.	12.8%	355,158	SC 13D
Oct 30, 2023	strome mezzanine fund, lp	3.3%	345,036	SC 13D/A
Feb 14, 2023	maggiore christopher d.	10.2%	979,744	SC 13D/A

Recent SEC filings of Zivo Bioscience, Inc.

View All Filings

Date Filed	Form Type	Document
May 13, 2024	10-Q	Quarterly Report
Apr 26, 2024	DEFA14A	DEFA14A
Apr 26, 2024	DEF 14A	DEF 14A
Apr 26, 2024	ARS	ARS
Apr 09, 2024	SC 13D/A	13D - Major Acquisition
Mar 15, 2024	10-K	Annual Report
Mar 14, 2024	SCHEDULE 13D/A	SCHEDULE 13D/A
Feb 15, 2024	8-K	Current Report
Feb 15, 2024	25-NSE	25-NSE

Peers (Alternatives to Zivo Bioscience, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Zivo Bioscience, Inc. News

Latest updates

Zivo Bioscience, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2	2018Q1	2017Q4
Revenue	202.7%	36.00	12.00	12.00	4.00	266	527	321	164	888	1,611	219	244	270	709	720	292	662	623	254	424	117
Gross Profit	202.6%	13.00	4.00	4.00	3.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Costs and Expenses	-	-	-	-	-	-	1,706	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-32.2%	1,288	1,901	1,577	1,827	1,970	1,673	1,749	2,084	1,755	3,365	1,030	2,426	3,773	1,574	2,037	968	1,617	1,495	1,335	-	-
S&GA Expenses	-100.0%	-	1,588	1,356	1,385	1,568	1,264	1,281	1,437	3,294	459	374	694	3,036	340	370	309	397	317	307	332	-
R&D Expenses	0.1%	313	312	221	442	402	409	468	647	447	1,295	437	1,576	467	526	948	366	559	555	774	-	-
Interest Expenses	106.1%	3.00	-43.70	33.00	32.00	3.00	209*	19.00	24.00	37.00	24.00	24.00	-	-	-	-	-	-	-	-	-	-
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	33.0%	-1,278	-1,908	-1,824	-2,070	-1,973	-1,551	-1,845	-2,218	-1,893	-3,502	-1,166	-2,542	-4,131	-1,781	-2,540	-3,057	-3,097	-4,118	-3,573	-	-
Net Income Margin	60.3%	-111.76*	-281.27*	-4.27*	-4.36*	-4.37*	-3.77*	-4.75*	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Free Cashflow	-137.4%	-1,699	-715	-1,969	-985	-2,128	-1,801	-2,048	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	46.9%	816	556	2,102	710	1,128	2,123	3,971	5,865	7,688	8,990	10,972	11,104	649	390	130	223	179	369	70.00	112	104
Current Assets	67.1%	711	425	1,948	530	928	1,902	3,729	5,601	7,454	8,960	10,935	11,062	458	168	130	223	179	369	70.00	112	104
Cash Equivalents	-100.0%	-	274	1,485	21.00	209	1,799	3,386	5,084	6,599	8,902	10,803	10,903	232	138	55.00	119	10.00	346	15.00	44.00	4.00
Net PPE	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Liabilities	11.7%	3,085	2,762	3,196	3,855	2,870	2,134	2,447	2,854	3,104	2,948	3,201	3,771	12,073	11,531	11,221	10,216	9,327	8,708	10,973	11,271	24,803
Current Liabilities	11.7%	3,085	2,762	3,174	3,804	2,791	2,028	2,315	2,697	2,959	2,948	3,198	3,642	11,941	11,394	11,100	10,094	9,327	8,708	10,973	11,271	24,803
Shareholder's Equity	-2.9%	-2,268	-2,205	-	-	-1,741	-10.62	1,524	3,010	4,585	6,042	7,771	7,333	-	-	-	-	-	-	-	-	-
Retained Earnings	-1.0%	-124,860	-123,581	-121,673	-119,848	-117,777	-115,804	-113,163	-112,327	-110,255	-107,059	-104,712	-103,128	-101,282	-99,063	-97,170	-93,667	-92,500	-89,957	-85,826	-84,044	-81,504
Additional Paid-In Capital	1.0%	122,589	121,373	120,577	116,694	116,027	115,792	114,679	115,328	114,830	113,092	112,474	110,452	89,438	87,748	85,673	83,268	82,949	81,223	74,565	72,544	56,619
Shares Outstanding	17.1%	2,790	2,382	1,742	1,570	1,570	1,570	1,570	1,570	1,570	1,570	1,570	-	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	17,300	-	-	-	28,300	-	-	-	29,200	-	-	-	27,358	-	-	-	18,826	-

Cashflow (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-137.4%	-1,699	-715	-1,969	-985	-2,128	-1,447	-1,488	-1,305	-2,861	-1,901	-1,801	-2,048	-1,052	-901	-564	-339	-783	-651	-1,326	-1,153	-576
Share Based Compensation	-	-	-	-	-	-	-	-	-	571	-	-	-	975	-	-	-	-	-	-	-	-
Cashflow From Investing	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cashflow From Financing	416.1%	1,563	-494	3,433	798	538	-139	-209	-209	559	1*	1,702	12,720	1,146	984	501	449	447	982	1,298	1,193	192

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

ZIVO Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
REVENUES:
Product revenue	$ 35,720	$ 0
Total revenues	35,720	0
COSTS OF GOODS SOLD
Product costs	23,218	0
Total costs of goods sold	23,218	0
GROSS MARGIN	12,502	0
COSTS AND EXPENSES:
General and administrative	975,574	1,568,377
Research and development	312,767	401,797
Total costs and expenses	1,288,341	1,970,174
LOSS FROM OPERATIONS	(1,275,839)	(1,970,174)
OTHER (EXPENSE):
Interest expense	(2,648)	(2,968)
Total other expense	(2,648)	(2,968)
NET LOSS	$ (1,278,486)	$ (1,973,142)
BASIC AND DILUTED LOSS PER SHARE	$ (0.47)	$ (1.26)
WEIGHTED AVERAGE BASIC AND DILUTED SHARES OUTSTANDING	2,748,294	1,569,943

ZIVO Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEET - USD ($)	Mar. 31, 2024	Dec. 31, 2023
CURRENT ASSETS:
Cash	$ 138,641	$ 274,380
Accounts receivable	3,735	3,735
Prepaid expenses	568,241	147,262
Total current assets	710,617	425,377
OTHER ASSETS:
Operating lease - right of use asset	73,721	98,280
Security deposit	32,058	32,058
Total other assets	105,779	130,338
TOTAL ASSETS	816,396	555,715
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT):
Accounts payable	705,841	993,090
Accounts payable - related party	211,170	172,670
Current portion of long-term operating lease	79,033	106,342
Convertible debentures payable	240,000	240,000
Loan Payable	460,053	0
Accrued interest	101,278	100,686
Accrued liabilities - employee bonus	1,287,920	1,148,770
Total current liabilities	3,085,295	2,761,558
LONG TERM LIABILITIES:	0	0
TOTAL LIABILITIES	3,085,295	2,761,558
STOCKHOLDERS' EQUITY (DEFICIT):
Common stock, $0.001 par value, 25,000,000 and 25,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 2,789,655 and 2,382,356 issued and outstanding at March 31, 2024, and December 31, 2023, respectively	2,791	2,383
Additional paid-in capital	122,588,510	121,373,488
Accumulated deficit	(124,860,200)	(123,581,714)
Total stockholders' equity (deficit)	(2,268,899)	(2,205,843)
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)	$ 816,396	$ 555,715

About Zivo Bioscience, Inc.

ZIVO Bioscience, Inc., a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. Its products indications include poultry gut health, bovine mastitis, canine joint health, human immune modification, algal biomass for human consumption, and biomass for supporting skin health / anti-aging. The company was formerly known as Health Enhancement Products, Inc. and changed its name to ZIVO Bioscience, Inc. in October 2014. ZIVO Bioscience, Inc. is headquartered in Bloomfield Hills, Michigan.

CEO	Mr. John B. Payne
WEBSITE	zivobioscience.com
INDUSTRY	Biotechnology
EMPLOYEES	8

Zivo Bioscience, Inc. Frequently Asked Questions

What is the ticker symbol for Zivo Bioscience, Inc.? What does ZIVO stand for in stocks?

ZIVO is the stock ticker symbol of Zivo Bioscience, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Zivo Bioscience, Inc. (ZIVO)?

As of Thu May 16 2024, market cap of Zivo Bioscience, Inc. is 22.6 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ZIVO stock?

You can check ZIVO's fair value in chart for subscribers.

What is the fair value of ZIVO stock?

You can check ZIVO's fair value in chart for subscribers. The fair value of Zivo Bioscience, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Zivo Bioscience, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ZIVO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Zivo Bioscience, Inc. a good stock to buy?

The fair value guage provides a quick view whether ZIVO is over valued or under valued. Whether Zivo Bioscience, Inc. is cheap or expensive depends on the assumptions which impact Zivo Bioscience, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ZIVO.

What is Zivo Bioscience, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 16 2024, ZIVO's PE ratio (Price to Earnings) is -3.19 and Price to Sales (PS) ratio is 356.62. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ZIVO PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Zivo Bioscience, Inc.'s stock?

In the past 10 years, Zivo Bioscience, Inc. has provided 0.354 (multiply by 100 for percentage) rate of return.